French biotech Pep-Therapy SAS is in the midst of raising a €20 million (US$21.62 million) round and, at the same time, prospecting for potential partners after winning FDA orphan drug designation for its bifunctional peptide Pep-010 in the treatment of pancreatic cancer. Pep-010 currently is moving to the conclusion of a phase Ib trial and the new money will fund phase II development.

Biopharmas raising money in public or private financings, including: Vivani.

Biopharmas raising money in public or private financings, including: Epicrispr, Hubble, Jaguar, Tribune.

Biopharmas raising money in public or private financings, including: Benitec, Character Biosciences, Cytonics, Genelux, Neuronos.

Biopharmas raising money in public or private financings, including: Cyclacel, Geovax, Surrozen, Tempero Bio, Transcode.

Hillstar Bio came out of stealth mode, announcing a $67 million series A financing round with investors including Droia Ventures, Frazier Life Sciences, Novo Holdings A/S and Lifearc Ventures.

Biopharmas raising money in public or private financings, including: Opus Genetics, Visen.

Biopharmas raising money in public or private financings, including: Akebia.

Biopharmas raising money in public or private financings, including: Ampersand, Genenta, Mineralys.